Free Trial
→ $30 stock to buy before Starlink goes public (WATCH NOW!) (From Paradigm Press) (Ad)tc pixel Free NUWE Stock Alerts

Nuwellis (NUWE) Competitors

Nuwellis logo
$1.11 -0.01 (-0.89%)
Closing price 04:00 PM Eastern
Extended Trading
$1.12 +0.00 (+0.45%)
As of 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NUWE vs. MODD, QNRX, MBAI, VVOS, and PAVM

Should you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include Modular Medical (MODD), Quoin Pharmaceuticals (QNRX), Check-Cap (MBAI), Vivos Therapeutics (VVOS), and PAVmed (PAVM). These companies are all part of the "medical equipment" industry.

How does Nuwellis compare to Modular Medical?

Modular Medical (NASDAQ:MODD) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

27.5% of Modular Medical shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 7.1% of Modular Medical shares are held by company insiders. Comparatively, 1.6% of Nuwellis shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Modular Medical has a net margin of 0.00% compared to Nuwellis' net margin of -211.86%. Modular Medical's return on equity of -245.85% beat Nuwellis' return on equity.

Company Net Margins Return on Equity Return on Assets
Modular MedicalN/A -245.85% -190.80%
Nuwellis -211.86%-6,094.26%-231.24%

In the previous week, Modular Medical had 1 more articles in the media than Nuwellis. MarketBeat recorded 3 mentions for Modular Medical and 2 mentions for Nuwellis. Modular Medical's average media sentiment score of 0.39 beat Nuwellis' score of 0.00 indicating that Modular Medical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Modular Medical
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nuwellis
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Nuwellis has higher revenue and earnings than Modular Medical. Modular Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Modular MedicalN/AN/A-$18.82M-$14.71N/A
Nuwellis$8.27M0.33-$17.52M-$90.92N/A

Modular Medical has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Modular Medical
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Nuwellis
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Summary

Modular Medical beats Nuwellis on 8 of the 13 factors compared between the two stocks.

How does Nuwellis compare to Quoin Pharmaceuticals?

Quoin Pharmaceuticals (NASDAQ:QNRX) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Quoin Pharmaceuticals has higher earnings, but lower revenue than Nuwellis. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Quoin PharmaceuticalsN/AN/A-$15.81M-$34.29N/A
Nuwellis$8.27M0.33-$17.52M-$90.92N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Quoin Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Nuwellis
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Quoin Pharmaceuticals has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.

8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 13.5% of Quoin Pharmaceuticals shares are owned by insiders. Comparatively, 1.6% of Nuwellis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Quoin Pharmaceuticals has a net margin of 0.00% compared to Nuwellis' net margin of -211.86%. Quoin Pharmaceuticals' return on equity of -535.00% beat Nuwellis' return on equity.

Company Net Margins Return on Equity Return on Assets
Quoin PharmaceuticalsN/A -535.00% -223.99%
Nuwellis -211.86%-6,094.26%-231.24%

In the previous week, Nuwellis had 1 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 2 mentions for Nuwellis and 1 mentions for Quoin Pharmaceuticals. Quoin Pharmaceuticals' average media sentiment score of 0.00 equaled Nuwellis'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Quoin Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nuwellis
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Quoin Pharmaceuticals beats Nuwellis on 8 of the 12 factors compared between the two stocks.

How does Nuwellis compare to Check-Cap?

Check-Cap (NASDAQ:MBAI) and Nuwellis (NASDAQ:NUWE) are both small-cap medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Check-Cap has higher earnings, but lower revenue than Nuwellis. Check-Cap is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Check-CapN/AN/A$4.14M-$2.77N/A
Nuwellis$8.27M0.33-$17.52M-$90.92N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Check-Cap
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Nuwellis
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Check-Cap has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.

1.1% of Check-Cap shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 0.5% of Check-Cap shares are owned by insiders. Comparatively, 1.6% of Nuwellis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Check-Cap has a net margin of 0.00% compared to Nuwellis' net margin of -211.86%. Check-Cap's return on equity of 0.00% beat Nuwellis' return on equity.

Company Net Margins Return on Equity Return on Assets
Check-CapN/A N/A N/A
Nuwellis -211.86%-6,094.26%-231.24%

In the previous week, Nuwellis had 1 more articles in the media than Check-Cap. MarketBeat recorded 2 mentions for Nuwellis and 1 mentions for Check-Cap. Check-Cap's average media sentiment score of 0.00 equaled Nuwellis'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Check-Cap
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nuwellis
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Check-Cap and Nuwellis tied by winning 6 of the 12 factors compared between the two stocks.

How does Nuwellis compare to Vivos Therapeutics?

Vivos Therapeutics (NASDAQ:VVOS) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Nuwellis has lower revenue, but higher earnings than Vivos Therapeutics. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vivos Therapeutics$17.44M0.55-$21.17M-$2.07N/A
Nuwellis$8.27M0.33-$17.52M-$90.92N/A

Vivos Therapeutics has a beta of 6.25, meaning that its stock price is 525% more volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500.

Vivos Therapeutics presently has a consensus target price of $2.58, suggesting a potential upside of 264.11%. Given Vivos Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Vivos Therapeutics is more favorable than Nuwellis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vivos Therapeutics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Nuwellis
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by company insiders. Comparatively, 1.6% of Nuwellis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vivos Therapeutics has a net margin of -121.37% compared to Nuwellis' net margin of -211.86%. Vivos Therapeutics' return on equity of -849.22% beat Nuwellis' return on equity.

Company Net Margins Return on Equity Return on Assets
Vivos Therapeutics-121.37% -849.22% -96.11%
Nuwellis -211.86%-6,094.26%-231.24%

In the previous week, Nuwellis had 1 more articles in the media than Vivos Therapeutics. MarketBeat recorded 2 mentions for Nuwellis and 1 mentions for Vivos Therapeutics. Vivos Therapeutics' average media sentiment score of 0.83 beat Nuwellis' score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vivos Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nuwellis
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Vivos Therapeutics beats Nuwellis on 13 of the 15 factors compared between the two stocks.

How does Nuwellis compare to PAVmed?

PAVmed (NASDAQ:PAVM) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

PAVmed has higher earnings, but lower revenue than Nuwellis. PAVmed is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PAVmed$70K115.00$400K-$22.77N/A
Nuwellis$8.27M0.33-$17.52M-$90.92N/A

PAVmed has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500.

PAVmed presently has a consensus target price of $65.00, suggesting a potential upside of 707.45%. Given PAVmed's higher probable upside, research analysts plainly believe PAVmed is more favorable than Nuwellis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PAVmed
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Nuwellis
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

19.9% of PAVmed shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 5.8% of PAVmed shares are owned by company insiders. Comparatively, 1.6% of Nuwellis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

PAVmed has a net margin of 564.79% compared to Nuwellis' net margin of -211.86%. PAVmed's return on equity of -242.99% beat Nuwellis' return on equity.

Company Net Margins Return on Equity Return on Assets
PAVmed564.79% -242.99% -17.25%
Nuwellis -211.86%-6,094.26%-231.24%

In the previous week, PAVmed had 1 more articles in the media than Nuwellis. MarketBeat recorded 3 mentions for PAVmed and 2 mentions for Nuwellis. PAVmed's average media sentiment score of 0.00 equaled Nuwellis'average media sentiment score.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
PAVmed
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nuwellis
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

PAVmed beats Nuwellis on 11 of the 12 factors compared between the two stocks.

Get Nuwellis News Delivered to You Automatically

Sign up to receive the latest news and ratings for NUWE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUWE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NUWE vs. The Competition

Export
MetricNuwellisMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$2.76M$7.14B$6.24B$11.86B
Dividend YieldN/A1.75%2.73%5.21%
P/E RatioN/A29.6029.0428.48
Price / Sales0.3355.86477.1060.43
Price / CashN/A24.9127.6236.52
Price / Book0.707.189.676.67
Net Income-$17.52M$158.34M$3.55B$332.64M
7 Day PerformanceN/A2.64%1.70%2.01%
1 Month Performance1.83%4.99%5.62%9.19%
1 Year Performance-97.37%-3.14%34.42%39.59%

Nuwellis Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NUWE
Nuwellis
0.4159 of 5 stars		$1.11
-0.9%		N/AN/A$2.76M$8.27MN/A70
MODD
Modular Medical
0.4314 of 5 stars		$4.17
-3.2%		N/AN/A$10.79MN/AN/A20
QNRX
Quoin Pharmaceuticals
0.6074 of 5 stars		$5.93
+8.8%		N/AN/A$10.67MN/AN/A4
MBAI
Check-Cap
0.0298 of 5 stars		$1.45
-1.4%		N/AN/A$10.57MN/AN/A80
VVOS
Vivos Therapeutics
3.2047 of 5 stars		$0.78
-7.9%		$2.58
+230.1%		N/A$10.55M$17.44MN/A160

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NUWE) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
The $1.75T "Backdoor" ticker (NOT Starlink)
When the SpaceX IPO launches, most investors will already be too late. The real opportunity isn't the IPO itse...
Behind the Markets | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel